In Finland, anti‐VEGF treatments are based on Finnish national guidelines for exudative AMD that allow fixed, pro re nata, and treat‐and‐extend protocols and bevacizumab, ranibizumab, and aflibercept intravitreal injections (Tuuminen et al., 2017). Here, VEGFA is linked to age-related macular degeneration.